Gland Pharma Limited
Bombay Stock ExchangeTotal Valuation
Gland Pharma Limited carries a market capitalization of 367.73B, placing it among publicly traded companies globally. Its enterprise value stands at 301.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 367.73B |
| Enterprise Value | 301.82B |
Valuation Ratios
Gland Pharma Limited trades at a trailing price-to-earnings ratio of 39.19.
| PE Ratio | 39.19 |
| PS Ratio | 5.28 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Gland Pharma Limited trades at an EV/EBITDA multiple of 30.63 and an EV/FCF ratio of 947.03. The EV/Sales ratio of 5.28 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.63 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.28 |
| EV / EBITDA | 30.63 |
| EV / EBIT | 30.63 |
| EV / FCF | 947.03 |
Financial Position
Gland Pharma Limited maintains a current ratio of 8.50, meaning it holds 8.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.15, indicating elevated leverage, while an interest coverage ratio of 20.58 demonstrates strong ability to service its debt obligations.
| Current Ratio | 8.50 |
| Quick Ratio | 3.79 |
| Debt / Equity | 7.15 |
| Debt / EBITDA | N/A |
| Interest Coverage | 20.58 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 203.50 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Gland Pharma Limited has paid 3.87B in income taxes, reflecting an effective tax rate of 33.44.
| Income Tax | 3.87B |
| Effective Tax Rate | 33.44 |
Stock Price Statistics
Gland Pharma Limited's stock has gained approximately 40.03953% over the past 52 weeks. The 50-day moving average sits at 1,872.37, while the 200-day moving average is 1,836.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | 40.03953% |
| 50-Day Moving Average | 1,872.37 |
| 200-Day Moving Average | 1,836.65 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Gland Pharma Limited generated 57.20B in revenue and converted that into 7.70B in net income, yielding earnings per share of 46.75. EBITDA reached 9.85B, while operating income came in at 9.85B.
| Revenue | 57.20B |
| Gross Profit | 36.73B |
| Operating Income | 9.85B |
| Pretax Income | 11.57B |
| Net Income | 7.70B |
| EBITDA | 9.85B |
| EBIT | 9.85B |
| Earnings Per Share (EPS) | 46.75 |
Margins
Gland Pharma Limited operates with a gross margin of 64.21, reflecting its pricing power and cost economics. The operating margin of 17.22 and net profit margin of 13.46 provide insight into operational efficiency.
| Gross Margin | 64.21 |
| Operating Margin | 17.22 |
| Pretax Margin | 20.23 |
| Profit Margin | 13.46 |
| EBITDA Margin | 17.22 |
Scores
Gland Pharma Limited posts an Altman Z-Score of 19.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 19.80 |